Stock Events

Stock Events

Search...

Immunovia AB

SEK0.7

0

+SEK0+0% Wednesday 09:24

Statistics

Day High

0.7

Day Low

0.7

52W High

7.83

52W Low

0.99

Volume

37,068

Avg. Volume

21,015

Mkt Cap

191,012

P/E Ratio

-

Dividend Yield

-

Dividend

-

Upcoming

Earnings

27NovExpected

Q4 2021

Q1 2022

Q2 2022

Q3 2022

Q1 2024

Q2 2024

Next

-0.24

-0.16

-0.08

-0.01

Expected EPS

N/A

Actual EPS

N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 0G8X.LSE. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Exact Sciences Corp. offers cancer screening and diagnostic tests, competing directly in the early detection market where Immunovia also operates.

Guardant Health

Guardant Health provides liquid biopsy tests for cancer diagnostics, overlapping with Immunovia's focus on early cancer detection using blood-based biomarkers.

Roche Holding AG develops diagnostic tools and technologies for detecting various diseases including cancer, similar to Immunovia's diagnostic solutions.

Illumina, Inc. offers genomic sequencing solutions used in cancer and other health diagnostics, competing in the broader market of molecular diagnostics.

Qiagen N.V. provides sample and assay technologies for molecular diagnostics, competing with Immunovia in the field of precision medicine and diagnostics.

Quest Diagnostics

Quest Diagnostics incorporates advanced diagnostics for conditions including cancer, directly competing with Immunovia's diagnostic tests.

Bio-Rad Laboratories

Bio-Rad Laboratories, Inc. specializes in clinical diagnostics and life science research, offering products that compete in the diagnostics market.

Fulgent Genetics

Fulgent Genetics, Inc. focuses on genetic testing to detect cancer and other diseases, competing with Immunovia's genomic and proteomic testing approaches.

Myriad Genetics

Myriad Genetics, Inc. provides molecular diagnostic tests that assess the risk of developing cancer, competing with Immunovia's focus on early detection and risk assessment.

About

Immunovia AB (publ), a diagnostic company, develops and commercializes blood-based diagnostics for cancer in Sweden and internationally. It offers IMMray PanCan-d, a blood-based test for the early detection of pancreatic cancer. The company was incorporated in 2007 and is headquartered in Lund, Sweden.

Show more...

CEO

Mr. Philipp Mathieu

Employees

39

Country

SE

ISIN

SE0006091997

Listings